Citius Oncology Reports Positive Phase 1 LYMPHIR Data in High-Risk DLBCL, Demonstrating High Response Rates

summarizeSummary

Citius Oncology, a subsidiary of Citius Pharmaceuticals, reported positive Phase 1 clinical trial results for LYMPHIR in high-risk DLBCL, showing strong efficacy and a favorable safety profile.

check_boxKey Events

• Positive Phase 1 Trial Results

  Citius Oncology announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR™ (E7777) in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

• High Efficacy Rates Observed

  The trial demonstrated an 86% overall response rate (ORR) at one month, including 57% complete responses (CR) and 29% partial responses (PR). One-year progression-free survival was 77% and overall survival was 84%.

• Favorable Safety Profile

  LYMPHIR was well-tolerated with no dose-limiting toxicities observed, and no Grade ≥3 LYMPHIR-related immune adverse events or infusion reactions were reported.

• Potential for Expanded Indication

  These results support exploring LYMPHIR's use as an immunomodulatory strategy to enhance CAR-T therapy in DLBCL, potentially expanding its market beyond its current FDA-approved indication for CTCL.

auto_awesomeAnalysis

Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, announced positive topline Phase 1 results for LYMPHIR™ (E7777) in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This is a significant development as it suggests potential for LYMPHIR beyond its current FDA-approved indication for CTCL. The high overall response rate (86%) and complete response rate (57%) in a challenging patient population, coupled with a favorable safety profile, provide an encouraging signal for further development. For a company facing a going concern warning and Nasdaq non-compliance, positive clinical data like this is crucial for demonstrating pipeline value and potentially attracting future investment or partnerships, which could alleviate financial pressures.